Form 4: BeOne Medicines GC Sells Shares Under 10b5-1 Plan

BeOne Medicines' SVP and General Counsel, Chan Henry Lee, exercised stock options and sold the resulting shares via American Depositary Shares under a pre-arranged trading plan.

Summary

• Chan Henry Lee, SVP and General Counsel of BeOne Medicines Ltd. (ONC), executed a series of transactions on February 4, 2026.
• Exercised a total of 21,580 share options with exercise prices ranging from $12.23 to $16.41 per ordinary share.
• Simultaneously sold 1,660 American Depositary Shares (ADSs) at prices of $348.79 and $350 per ADS.
• Each ADS represents 13 Ordinary Shares, meaning a total of 21,580 ordinary shares were sold, directly corresponding to the number of options exercised.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
• Following these transactions, the reporting person beneficially owns 223,106 Ordinary Shares directly and a total of 223,920 remaining share options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, the execution under a pre-arranged 10b5-1 plan suggests a planned liquidity event rather than a reflection of management's immediate outlook on the company's future performance.

Positives

• The exercise of options indicates the reporting person is realizing value from their equity compensation.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned liquidity event rather than a reaction to recent company news.

Negatives

• The sale of shares by a senior executive could be perceived negatively by some investors, as it reduces their direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common for executives to manage their personal finances and diversify their holdings. While a sale reduces direct equity exposure, the pre-scheduled nature often mitigates concerns about immediate negative sentiment regarding the company's prospects, distinguishing it from opportunistic sales.

Comparison to Industry Standards

• StockSavvy.ai observes that the exercise of stock options and subsequent sale of shares is a standard practice for executives across various industries, including pharmaceuticals and biotechnology, to monetize vested equity compensation.
• This type of transaction is typically part of a long-term financial strategy rather than a reaction to short-term market conditions.
• For instance, similar planned sales are seen at companies like Pfizer or Novartis, where executives regularly exercise and sell shares as part of their compensation packages, often through 10b5-1 plans to ensure compliance and avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret the sale as a planned diversification by a senior executive, potentially leading to neutral or slightly negative sentiment depending on individual investor perspectives on insider selling.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Recommendation

The insider transaction, executed under a pre-arranged 10b5-1 plan, represents a routine liquidity event for an executive and does not provide new fundamental information about BeOne Medicines' operational performance or strategic direction. Investors should hold their positions and await further company-specific news or financial reports for a more comprehensive investment decision.

Keywords

BeOne Medicines, ONC, SEC Form 4, Insider Trading, Stock Options, American Depositary Shares, ADS, Chan Henry Lee, SVP General Counsel, 10b5-1 Plan, Equity Compensation, Executive Compensation